We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Boehringer Ingelheim Pharmaceuticals, Inc.today announced that the U.S. Food and Drug Administration (FDA) has provided full approval for Praxbind®, the specific reversal agent for Pradaxa® (dabigatran etexilate mesylate).